AMRN Amarin Corporation plc - Americ

2.98
-0.07  -2%
Previous Close 3.05
Open 3.05
Price To book 0.00
Market Cap 806.67M
Shares 270,695,000
Volume 779,633
Short Ratio 3.25
Av. Daily Volume 1,383,530

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Interim analysis announced September 12, 2016 - trial to proceed.Second interim analysis due late 3Q 2017. Final data due mid-2018.
Vascepa REDUCE-IT outcomes trial
High Triglycerides With Mixed Dyslipidemia

Latest News

  1. 3 Healthcare Stocks for Savvy Investors
  2. ETFs with exposure to Amarin Corp. Plc : May 22, 2017
  3. Amarin Announces Expanded Research Relationships and Studies to Help Improve Cardiovascular Care
  4. Amarin Corp. Plc :AMRN-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
  5. Is the Options Market Predicting a Spike in Amarin Corporation (AMRN) Stock?
  6. Edited Transcript of AMRN earnings conference call or presentation 3-May-17 12:00pm GMT
  7. Investor Network: Amarin Corporation Plc Sponsored ADR to Host Earnings Call
  8. Amarin reports 1Q loss
  9. Amarin Reports First Quarter 2017 Financial Results and Provides Update on Operations
  10. Investor Calendar Invites You to the Amarin First Quarter 2017 Earnings Conference Call and Webcast Live on Wednesday, May 3, 2017
  11. ETFs with exposure to Amarin Corp. Plc : April 26, 2017
  12. Amarin to Report First Quarter 2017 Results and Host Conference Call on May 3, 2017
  13. Overseas Earnings Estimated to Outdo US: Top 5 Gainers
  14. 3 Stocks the Smartest Investors Are Buying Right Now
  15. 3 Stocks That Could Make You Rich
  16. 4 Biotech Stocks With Jaw-Dropping Growth Potential
  17. Amarin Corporation CEO, John Thero, to Chair the American Heart Association’s Heart & Stroke Ball in New York City
  18. Amarin Reaches the Onset of Approximately 80% of the Target Aggregate Number of Primary Major Adverse Cardiovascular Events Within the REDUCE-IT Study
  19. Amarin Announces Publication of REDUCE-IT Cardiovascular Outcomes Study Rationale and Design in Clinical Cardiology